

SCHEDULING STATUS:

S4

PROPRIETARY NAME (and dosage form):

NIDASALL 200 (Tablets)

NIDASALL 400 (Tablets)

COMPOSITION:

NIDASALL 200: Each tablet contains metronidazole 200 mg

NIDASALL 400: Each tablet contains metronidazole 400 mg

PHARMACOLOGICAL CLASSIFICATION:

A 20.2.6 - Medicines against protozoa

PHARMACOLOGICAL ACTION:

Metronidazole has anti-protozoal activity against *Trichomonas vaginalis*, *Entamoeba histolytica* and *Giardia lamblia*. Metronidazole has bactericidal activity *in vitro* against several anaerobic organisms.

INDICATIONS:

1. *Trichomonas* infections in both males and females.
2. Symptomatic forms of amoebiasis.
3. Lambliasis and Vincent's angina.
4. Treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly *Bacteroides fragilis* and other species of *Bacteroides* and including other species for which metronidazole is bactericidal.
5. Prevention of post-operative infections due to anaerobic bacteria.

CONTRAINDICATIONS:

Hypersensitivity to metronidazole.

In patients with blood dyscrasias or with active disease of the central nervous system.

The use of metronidazole should be avoided during pregnancy and lactation.

WARNINGS

Pseudomembranous colitis has been reported with the use of metronidazole. Alcohol should be avoided during treatment as metronidazole may provoke a disulfiram like reaction. Metronidazole enhances the anticoagulant effect of warfarin.

DOSAGE AND DIRECTIONS FOR USE:

Tablets should be swallowed with a half glass of water during or after meals.

Seven days treatment should be satisfactory for most patients. Prolonged treatment can be used if the physician considers it to be necessary. Children over 10 years may be given a suitable proportion of the adult dosage according to body-mass.

1. Treatment of Anaerobic Infections:

Adults and children over 12 years: 400 mg three times a day.

Children under 12 years: 7,5 mg per kg body-mass three times a day.

2. Prevention of Anaerobic Infections:

Gynaecological Surgery:

Adults: 2 g as a single dose followed by 200 mg three times a day until pre-operative withholding of solids and liquids becomes necessary. Medication with 200 mg three times daily should be resumed after the operation and continued for up to seven days.

3. Vincent's Angina:

Adults and children over 12 years: 200 mg three times a day for three days or 400 mg in the morning and evening for three days.

4. Treatment of Trichomonas Infections:

To prevent re-infection to consort should receive a similar course of treatment concurrently.

Adults and children over 12 years: either 200 mg three times daily for seven days or, 800 mg in the morning and 1,2 g in the evening for two days.

5. Treatment of Amoebic Infections:

Adults and children over 12 years: 800 mg three times a day for 5 - 10 days.

6. Treatment of Lambliasis:

Adults and children over 12 years: 2g once daily for three days.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:

Side effects include gastro-intestinal discomfort, anorexia, nausea, coated tongue, dry mouth and unpleasant taste, headache, pruritus and skin rash. Other side-effects are vomiting, diarrhoea, weakness, vertigo, ataxia, depression, insomnia, drowsiness, urethral discomfort and darkening of the urine. There may be temporary leucopenia and bone marrow depression. Peripheral neuropathy has been reported in patients on prolonged therapy. Transient fall in blood pressure has been reported. It may therefore be advisable to lower dosage of any antihypertensive drug, which may be given concurrently with **NIDASALL**.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

See "Side effects"

In recent overdosage gastric lavage is recommended. Further treatment is symptomatic and supportive.

IDENTIFICATION:

400 mg Tablets: Yellow, biconvex, scored tablet.

200 mg Tablets: White, biconvex, scored tablet.

PRESENTATION:

400 mg Tablets: Securitainers containing 100 or 500 tablets.

"Ziploc" patient ready L.D.P.E. plastic bags of different pack sizes (5, 14 or 21 tablets).

200 mg Tablets: Securitainers containing 250 tablets.

"Ziploc" patient ready L.D.P.E. plastic bags of different pack sizes (21 or 28 tablets).

STORAGE INSTRUCTIONS:

Store at or below 25 °C. Protect from light and moisture.

KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:

400 mg Tablets: 28/20.2.6/0037

200 mg Tablets: 28/20.2.6/0036

NAME AND BUSINESS ADDRESS OF APPLICANT:

Innovata Pharmaceuticals (Pty) Ltd.

Crownwood Office Park

100 Northern Parkway

Ormonde

Johannesburg

2091

South Africa

DATE OF PUBLICATION OF THIS PACKAGE INSERT:

October 2020

CODE: PI/NID/002

SKEDULERINGSSTATUS:**S4****EIENDOMSNAAM (en doseervorm:****NIDASALL 200 (Tablette)****NIDASALL 400 (Tablette)****SAMESTELLING:****NIDASALL 200:** Elke tablet bevat metronidasool 200mg**NIDASALL 400:** Elke tablet bevat metronidasool 400mg**FARMAKOLOGIESE KLASSIFIKASIE:**

A20.2.6. Middels teen protosoe.

FARMAKOLOGIESE WERKING:

Metronidasool het 'n antiprotosoe werking en is aktief teen *Trichomonas vaginalis*, *Entamoeba histolytica* en *Giardia lamblia*. Metronidasool is *in-vitro* bakteriedodend vir verskeie anaerobiese organismes.

INDIKASIES:

1. *Trichomonas* infeksies by mans sowel as vrouens.
2. Alie vorme van amebiase.
3. Lambliaze en Vincent se angina.
4. Behandeling van infeksies waar anaerobiese bakterie geïdentifiseer is of as patogene vermoed word, veral *Bacteroides fragilis* en ander spesies van *Bacteroides* asook ander spesies waar metronidasool bakteriedodend is.
5. Voorkoming van na operatiewe infeksie veroorsaak deur anaerobiese bakterieë.

KONTA-INDIKASIES:

Oorgevoeligheid vir metronidasool.

By pasiënte met bloedsiekte of met 'n aktiewe siektetoestand van die sentrale senuweestelsel.

Die gebruik van metronidasool tydens swangerskap en borsvoeding moet vermy word.

WAARSKUWINGS:

Pseudomembraneuse kolitis is al gerapporteer met die gebruik van metronidasool.

Alkohol moet nie gedurende die behandeling met metronidasool geneem word nie aangesien dit aanleiding tot 'n disulfiram-tipe reaksie kan gee.

Metronidasool verhoog die anti-stollende effek van warfariën.

DOSIS EN GEBRUIKSAANWYSINGS:

Tablette moet gesluk word met 'n halwe glas water gedurende of na etes.

Behandeling van sewe dae behoort normaalweg vir meeste pasiënte voldoende te wees.

Langdurige behandeling kan toegepas word indien die geneesheer dit nodig vind.

Kinders bo die ouderdom van 10 jaar kan geskikte hoeveelhede van die volwasse dosis, na gelang van die liggaamsmassa ontvang.

1. Behandeling van Anaerobiese Infeksies:**Volwassenes en kinders ouer as 12 jaar:** 400 mg drie maal per dag.**Kinders onder 12 jaar:** 7,5 mg per kg liggaamsmassa drie maal per dag.**2. Voorkoming van Anaerobe Infeksies:***Ginekologiese Chirurgie.***Volwassenes:** 2 g as 'n enkel dosis gevolg deur 200 mg drie maal per dag, totdat vooroperatiewe weerhouding van vaste stowwe en vloeistowwe nodig word.

Behandeling met 200 mg drie maal per dag moet na die operasie hervat word en vir tot sewe dae voortgesit word.

3. Vincent se Angina:**Volwassenes en kinders ouer as 12 jaar:** 200 mg drie maal per dag vir 3 dae of 400 mg soggens en saans vir drie dae.**4. Behandeling van Trichomonas Infeksies:**

(Om herinfeksie te voorkom moet die konsort gelyktydig 'n soortgelyke kursus van behandeling ontvang).

Volwassenes en kinders ouer as 12 jaar: 200 mg drie maal per dag vir sewe dae of 800 mg soggens en 1,2 g saans vir twee dae.**5. Behandeling van Amebe Infeksies:****Volwassenes en kinders ouer as 12 jaar:** 800 mg drie maal per dag vir 5 - 10 dae.**6. Behandeling van Lambliaze:****Volwassenes en kinders ouer as 12 jaar:** 2 g een maal per dag vir 3 dae.**NEWE-EFFEKTE EN SPESIALE VOORSORGMAATREËLS:**

Neuwe-effekte is onder andere maagdermangemak, verminderde eetlus, naarheid, aangepakte tong, droë mond en slegtesmaak, hoofpyn, pruritus en veluitslag. Ander nuwe-effekte wat kan voorkom is vomering, diarree, swaakteid, duiseligheid, ataksie, depressie, slaaploosheid, lomerigheid, uretrale ongemak en verdonkering van die urien. Tydelike leukopenie en beenmurgonderdrukking kan soms voorkom. By pasiënte wat landurige behandeling ontvang het, is perifere neuropatie al aangemeld. Kortstondige verlaging van die bloeddruk is gerapporteer. Dit is dus gewens om die dosisse van enige antihypertensiewe middels wat saam met **NIDASALL** geneem word, te verlaag.

BEKENDE SIMPTOME VAN OORDOSERING EN BESONDERHEDE VAN DIE BEHANDELING DAARVAN:

Sien nuwe-effekte.

Vroegtydige maagspoeling word aanbeveel. Verdere behandeling is simptomaties en ondersteunend.

IDENTIFIKASIE:**400 mg Tablette:** Geel, bikonvekse, gekepte tablet.**200 mg Tablette:** Wit, bikonvekse, gekepte tablet.**AANBIEDING:****400 mg Tablette:** Sekurainers wat 100 of 500 tablette bevat.

L.D.P.E. plastiese 'ziploc' pasiënt gereed pakkette van verskillende pakgroottes (5, 14 of 21 tablette)

200 mg Tablette: Sekurainers bevat 200 tablette.

L.D.P.E. plastiese 'ziploc' pasiënt gereed pakkette van verskillende pakgroottes (21 of 28 tablette)

BERGINGSANWYSINGS:

Berg benede 25 °C. Beskerm teen lig en vog.

HOU BUITE DIE BEREIK VAN KINDERS.

REGISTRASIENOMMERS:**400 mg Tablette:** 28/20.2.6/0037**200 mg Tablette:** 28/20.2.6/0036**NAAM EN BESIGHEIDSADRES VAN DIE APPLIKANT:**

Innovata Pharmaceuticals (Edms) Bpk.

Crownwood Office Park

Northern Parkway 100

Ormonde

Johannesburg

2091

Suid-Afrika

DATUM VAN PUBLIKASIE VAN HIERDIE VOUBILJET:

Oktobor 2020

KODE: PI/NID/002

27/01/2022





JET PRINTERScc

PRINTERS PROOF

File Number	
Repro Ticket	
Customer	
Product	NIDASALL 200 (Tablets) NIDASALL 400 (Tablets)
Code	PI/NID/002
Flat Size	330 (L) X 100 (W)
Folded Size	
Pharma Code	
Colours	BLACK
Proof No	2
Date	24/01/2022
Operator	
Proof Reader	

PLEASE CHECK PROOF CAREFULLY

Although we endeavour to proofread proofs accurately, JET cannot accept responsibility for errors once proofs have been signed and approved by our clients.

☐ Make amendments and supply another proof

☐ APPROVED – PLEASE PROCEED

Approved by	
Signature	
Date	